Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
857 Development of an mRNA cancer vaccine platform enabling flexible antigen exchange and dendritic cell selected delivery to overcome immune tolerance
- 11Samyang Biopharmaceuticals Corp., Pangyo, Republic of Korea
- 22Samyang Biopharamaceuticals Inc, Seongnamsi, Republic of Korea
- 3Samyang Biopharmaceuticals Corporation, Gyeonggi-do, Korea, Republic of
Related
- Dendritic computation for abstract rule-based flexible decision-making
- A Double-Edged Sword: The Dichotomous Roles of Dendritic Cell Subsets in Shaping CD8+ T Cell Immunity and Tolerance Within the Tumor Microenvironment
- Same Factor, Different Branches: Context-Dependent Control of Dendritic Development by Lhx2
- Mathematical model for visual cortical development based on molecular mechanisms underlying the generation and elimination of dendritic spines
- BRIDGE: A broad-host platform for interkingdom DNA delivery enabling the genetic domestication of phylogenetically diverse yeasts
BibTeX
@article{kim2026development,
title = {{857 Development of an mRNA cancer vaccine platform enabling flexible antigen exchange and dendritic cell selected delivery to overcome immune tolerance}},
author = {So-Young Kim and Helen Cho and Sojin Lee},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0857},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0857},
note = {CC BY},
}
RIS
TY - JOUR
TI - 857 Development of an mRNA cancer vaccine platform enabling flexible antigen exchange and dendritic cell selected delivery to overcome immune tolerance
AU - So-Young Kim
AU - Helen Cho
AU - Sojin Lee
PY - 2026
DA - 2026/11/08
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0857
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0857
SN - 2051-1426
ER -